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OBJECTIVE—Tumor necrosis factor- (TNF-) and interleu-
kin-1 beta (IL-1) are elevated in the vitreous of diabetic patients
and in retinas of diabetic rats associated with increased retinal
vascular permeability. However, the molecular mechanisms un-
derlying retinal vascular permeability induced by these cytokines
are poorly understood. In this study, the effects of IL-1 and
TNF- on retinal endothelial cell permeability were compared
and the molecular mechanisms by which TNF- increases cell
permeability were elucidated.
RESEARCH DESIGN AND METHODS—Cytokine-induced
retinal vascular permeability was measured in bovine retinal
endothelial cells (BRECs) and rat retinas. Western blotting,
quantitative real-time PCR, and immunocytochemistry were per-
formed to determine tight junction protein expression and
localization.
RESULTS—IL-1 and TNF- increased BREC permeability, and
TNF- was more potent. TNF- decreased the protein and mRNA
content of the tight junction proteins ZO-1 and claudin-5 and
altered the cellular localization of these tight junction proteins.
Dexamethasone prevented TNF-–induced cell permeability
through glucocorticoid receptor transactivation and nuclear fac-
tor-kappaB (NF-B) transrepression. Preventing NF-B activa-
tion with an inhibitor B kinase (IKK) chemical inhibitor or
adenoviral overexpression of inhibitor B alpha (IB) reduced
TNF-–stimulated permeability. Finally, inhibiting protein kinase
C zeta (PKC) using both a peptide and a novel chemical
inhibitor reduced NF-B activation and completely prevented the
alterations in the tight junction complex and cell permeability
induced by TNF- in cell culture and rat retinas.
CONCLUSIONS—These results suggest that PKC may provide
a speciﬁc therapeutic target for the prevention of vascular
permeability in retinal diseases characterized by elevated TNF-,
including diabetic retinopathy. Diabetes 59:2872–2882, 2010
T
he cause of vision loss in diabetic retinopathy is
complex and remains incompletely understood;
however, changes in blood vessel permeability
and macular edema are associated with loss of
visual acuity (1–5), with center point thickness and ﬂuo-
rescein leakage combined with age accounting for 33% of
the variation in visual acuity (5). A growing body of
evidence suggests that diabetic retinopathy includes a
neuroinﬂammatory component, with increased expression
of cytokines, microglia activation, leukostasis, and vascu-
lar permeability (6–9). Increased levels of interleukin-1
beta (IL-1) and tumor necrosis factor- (TNF-) have
been detected in the vitreous of diabetic patients with
proliferative diabetic retinopathy (10,11) and in diabetic
rat retinas (6,7,12). Moreover, intravitreal administration
of IL-1 increases vascular permeability, associated with
nuclear factor-kappaB (NF-B) activation, increased leu-
kocyte adhesion, and retinal capillary cell death (13,14).
TNF- also increases leukocyte adhesion to retinal endo-
thelium (15) and blood–retinal barrier (BRB) permeability
(16). The inhibition of TNF- with etanercept, a soluble
TNF- receptor, inhibits NF-B activation, leukostasis,
and BRB breakdown in diabetic rat retinas (12). Alto-
gether, these ﬁndings indicate that proinﬂammatory cyto-
kines contribute to vascular permeability in diabetic
retinopathy.
Changes in retinal vascular permeability may result
from alterations of the tight junction complex. Tight
junctions are composed of a combination of more than 40
proteins including the transmembrane proteins occludin,
the claudin family, and the junction adhesion molecule
(JAM) family, several peripheral membrane-associated
proteins, including members of the zonula occludens (ZO)
family, and several regulatory proteins (17). To date,
evidence has been provided for the presence of occludin,
claudin-5, ZO-1, and JAM-A in retinal vascular endothelium
(18–21). Changes in occludin content, localization, and
phosphorylation occur in response to vascular endothelial
growth factor (VEGF) regulating endothelial permeability
(18,19,22–24). Gene deletion studies have shown claudin-5
to be essential for blood–brain barrier function (25), and
likely for the BRB as well. Recent studies demonstrated
that ZO proteins are essential for the formation and
organization of tight junction complex assembly (26,27).
Therefore, changes in occludin, claudin-5, or ZO-1 likely
contribute to alterations in endothelial permeability, in
response to inﬂammatory cytokines.
Although several studies support the involvement of
proinﬂammatory cytokines in BRB breakdown in diabetes,
little attention has been given to the molecular mecha-
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the hypothesis that alterations to the tight junction protein
complex confer endothelial permeability in response to
TNF- and to determine the signaling pathways underlying
TNF--induced permeability.
TNF- was shown to regulate permeability in an NF-B-
dependent mechanism by downregulating both claudin-5
and ZO-1 expression. Further, protein kinase C zeta
(PKC) activity is essential for TNF-–induced endothelial
permeability, partly through NF-B activation, suggesting
that targeting PKC may provide a novel therapy to control
retinal vascular permeability.
RESEARCH DESIGN AND METHODS
Materials used to carry out the experiments are described in the supple-
mentary Materials and Methods in the online appendix available at
http://diabetes.diabetesjournals.org/cgi/content/full/db09-1606/DC1.
Primary bovine retinal endothelial cell culture. Bovine retinal endothe-
lial cells (BRECs) were isolated and grown as previously described (28),
except medium was supplemented with 8 g/ml tylosin. For experimenta-
tion, BRECs were grown to conﬂuence and then cell culture media was
changed to MCDB-131 medium supplemented with 1% FBS, 0.01 ml/ml
antibiotic/antimycotic, and 8 g/ml tylosin for one day and exposed to
IL-1 or TNF-.
Measurement of BREC permeability. BREC monolayer permeability to 70
kDa rhodamine isothiocyanate dextran (Sigma-Aldrich, St. Louis, MO) was
measured exactly as described previously (24). The average Po for control
conditions was 2.77  10
6 cm/s.
Animal model. Male Sprague-Dawley rats (Charles River Laboratories, Wilming-
ton, MA) weighing 150–175 g were used to evaluate retinal vascular permeability
and tight junction proteins localization in retinal blood vessels. Animals were
housed under a 12-h light/dark cycle with free access to water and a standard rat
chow. All experiments were conducted in accordance with the Association for
Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals
in Ophthalmic and Vision Research, and were approved and monitored by the
Institutional Animal Care and Use Committee (IACUC) at the Penn State College
of Medicine. Under anesthesia (66.7 mg/kg ketamine and 6.7 mg/kg xylazine), the
animal received an intravitreal injection of TNF- or vehicle (2.5 l/eye) with a 5
l Hamilton syringe (Hamilton Company, Reno, NV) through a puncture created
by a 32-gauge needle. The animals were assessed for retinal permeability with
Evans blue assay, 24 h after receiving the intravitreal injection of either PBS with
1% BSA, 10 ng TNF-, 280 ng PKCI-1, or TNF- plus PKCI-1. In a separate study,
retinas were harvested 4 h after injection, immunolabeled for tight junction
proteins, and analyzed by confocal microscopy.
Evans blue assay. Accumulation of the albumin binding dye Evans blue was
used to assess changes in retinal vascular permeability. Evans blue dye
accumulation in the retina was quantiﬁed using a published protocol (29),
with normalization to blood plasma after 2-h circulation and expressed as
microliters of plasma per gram of retina (dry weight) per hour of circulation.
Assessment of cell viability. The LIVE viability assay (Molecular Probes,
Invitrogen, Carlsbad, CA) was used for the assessment of cell viability
according to manufacturer’s instructions, as described in the supplementary
Materials and Methods.
Caspase-3/7 activity assay. Caspase-3/7 activity was measured by the
Apo-ONE Homogenous caspase-3/7 assay (Promega, Madison, WI), according
to the manufacturer’s instructions, as brieﬂy described in the supplementary
Materials and Methods.
Western blotting. Western blotting of cellular lysates was performed as
described in the supplementary Materials and Methods.
RNA extraction and reverse transcription. RNA extraction and reverse
transcription were performed as described in the supplementary Materials
and Methods.
Quantitative real-time PCR. Quantitative real-time PCR (qPCR) analysis
was performed using the 7,900 HT Sequence Detection System in 384-well
optical plates using TaqMan Universal PCR Master Mix Assay-on-Demand and
Assay-by-Design primers and probes (Applied Biosystems) as previously
described (30). Primer/probes used were as follows: claudin-5 Bt03288088_s1,
occludin Bt03255225_m1, IL-8 Bt03211907_g1, and bovine ZO-1 speciﬁc
primers 5-AGAAAGATGTTTATCGTCGCATCGT-3 (forward), 5-ATTCCT
TCTCATATTCAAAATGGGTTCTGA-3 (reverse), and 6-carboxy-ﬂuorescein
(FAM) 5-ACCCACATCGGATTCT-3 minor groove binding (MGB) probe. For
each sample, qPCR were performed in triplicate and relative quantities were
calculated using ABI SDS 2.0 RQ software and the 2
		Ct analysis method
(31), with glyceraldehyde-3-phosphate dehydrogenase (Bt03210919_g1) as the
endogenous control.
Immunocytochemistry. Tight junction protein cellular localization was
evaluated by immunocytochemistry, as previously described (32). Cells were
incubated with a rat anti-ZO-1 monoclonal antibody culture supernatant (1:5),
rabbit polyclonal anti-claudin-5 (1:500), or anti-occludin (1:300) antibodies
overnight at 4°C. Primary antibodies were detected with Alexa Fluor 647-
conjugated anti-rat IgG (Molecular Probes, Invitrogen) or Cy3-conjugated
anti-rabbit IgG secondary antibodies (Jackson Immunoresearch Laboratories,
West Grove, PA). Coverslips were mounted onto slides using Aqua Poly/Mount
(Aquamount; Polysciences, Warrington, PA) and analyzed in a Leica TCS SP2
AOBS confocal microscope. Ten confocal Z-stacks were collected over a
depth of 2.56 m and projected onto one image. ZO-1 and occludin localiza-
tion in retinal vessels were assessed by immunohistochemistry in whole
retinas, as described previously (33). The retinas were incubated with
monoclonal anti-occludin (1:50) and polyclonal anti-ZO-1 (1:50) antibodies for
three days at 4°C. Primary antibodies were detected with Cy2-conjugated
anti-mouse IgG and Cy3-conjugated anti-rabbit IgG secondary antibodies
(Jackson Immunoresearch Laboratories) for 24 h at 4°C. After incubation,
retinas were washed, mounted in slides with Aqua Poly/Mount, and analyzed
on a Leica TCS SP2 AOBS confocal microscope.
Adenovirus-mediated IB overexpression. IB was expressed using
the AdEasy adenoviral vector system, as described (34). Subconﬂuent cells
were transduced with adenovirus expressing IB (AdIB) or with an empty
expression cassette as control (AdEmpty) at a multiplicity of infection of
20,000 for6hi nMCDB complete medium. After incubation, cells were washed
and MCDB media supplemented with 1% serum was added for a further 24 h.
Successful viral infection was followed by ﬂuorescence microscopy because
the AdEasy vector contains a green ﬂuorescent protein (GFP) cassette
incorporated into the viral vector. More than 80% of the cells expressed
detectable amounts of GFP after 30 h of adenoviral infection.
Luciferase reporter assay. A 293T/NFB-luc stable reporter cell line (Pa-
nomics-Affymetrix, Fremont, CA) was used to evaluate NF-B transcription
factor activity. These cells maintain a chromosomal integrated luciferase
reporter gene regulated by multiple copies of the NF-B response element.
After treatments, cells were harvested and lysed with Passive Lysis Buffer
(Promega), and the luciferase activity was measured using the Dual-Lucif-
erase Reporter Assay system (Promega) according to manufacturer’s instruc-
tions. Luciferase activity was normalized to the total protein content of each
sample.
Statistical analysis. Results are expressed as mean 
 SEM. Data were
analyzed using Student t test or one-way ANOVA followed by Dunnett or
Bonferroni post hoc test. A value of P  0.05 was considered signiﬁcant. Prism
4.0 (GraphPad Software, San Diego, CA) was used for all statistical analysis.
RESULTS
IL-1 and TNF- increase BREC permeability. BRECs
grown on transwell ﬁlters were exposed to increasing con-
centrations and various times of IL-1 and TNF-, and the
monolayer permeability was evaluated. IL-1 signiﬁcantly
increased cell permeability at a concentration of 10 ng/ml
(220.3 
 34.2% of control; Fig. 1A), and this effect was
statistically signiﬁcant after 24 h of treatment (Fig. 1B).
Similarly, TNF- increased cell permeability in a concentra-
tion- and time-dependent manner. However, TNF- was
maximally effective at a concentration of 5 ng/ml (365.3 

47.8% of control, Fig. 1C) and at a shorter time point than
IL-1 (6 h, Fig. 1D). To ensure that the increase in perme-
ability induced by the cytokines was not due to cell death, the
effect of IL-1 and TNF- on BREC viability was evaluated
using IL-1 at 10 ng/ml and TNF- at 5 ng/ml. IL-1 had no
effect on cell viability. TNF--induced a signiﬁcant decrease
in cell viability after 24 h of treatment (70.9 
 2.6% of
control), but no effect was observed after6ho fexposure
(Fig. 1E). The effect of IL-1 and TNF- on caspase-3/7
activity, a marker of apoptosis, was also evaluated. IL-1 had
no effect on caspase-3/7 activity, whereas TNF- induced a
signiﬁcant increase in caspase-3/7 activity, but again only
after 24 h of exposure (Fig. 1F). Therefore, the increase in
cell permeability induced by TNF- after6ho fexposure was
not due to cell death. Because the effect of TNF- was more
robust than that of IL-1, the molecular mechanisms under-
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were further investigated.
TNF- alters tight junction protein content and lo-
calization. To determine the effect of TNF- on expres-
sion of speciﬁc tight junction proteins, BRECs were
exposed to 5 ng/ml TNF- for 0.5 and 6 h and the protein
contents of ZO-1, claudin-5, and occludin were determined
by Western blotting. TNF- signiﬁcantly decreased ZO-1
content (58.2 
 6.5% of control) after 6 h of exposure (Fig.
2A). Claudin-5 content was rapidly reduced after 0.5 h of
treatment (70.8 
 7.0% of control, Fig. 2B) ,a n d6ho f
TNF- exposure further downregulated claudin-5 content
(57.6 
 8.7% of control). In contrast, TNF- increased
occludin content (130.6 
 6.6% of control; Fig. 2C). To
determine whether alterations in protein content were due
to changes in mRNA expression, total mRNA content was
evaluated by qPCR 6 h after TNF- exposure. TNF-
signiﬁcantly decreased ZO-1 (74.6 
 3.3% of control; Fig.
2D) and claudin-5 mRNA content (80.9 
 5.7% of control;
Fig. 2E) but induced a twofold increase in occludin mRNA
(Fig. 2F). To investigate whether TNF- alters the tight
junction complex at the cell membrane, the cellular local-
ization of the tight junction proteins were evaluated by
immunocytochemistry and confocal microscopy. In con-
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FIG. 1. IL-1 and TNF- increase retinal endothelial cell permeability. A–D: BRECs were grown to conﬂuence on transwell ﬁlters and then
exposed to IL-1 or TNF- in a concentration- and time-dependent manner. The monolayer permeability to 70 kDa dextran was measured as
described in RESEARCH DESIGN AND METHODS. A: Cells were treated with 1, 10, and 100 ng/ml IL-1 for 24 h. B: Cells were treated with 10 ng/ml IL-1
for 0.5, 6, and 24 h. C: Cells were treated with 1, 2.5, 5, and 10 ng/ml TNF- f o r6h .D: Cells were treated with 5 ng/ml TNF- for 0.5, 6, and 24 h.
E and F: IL-1 and TNF- effect on cell viability. BRECs were treated with 10 ng/ml IL-1 or 5 ng/ml TNF- for 6 and 24 h. E: Relative cell viability
was measured by calcein AM cleavage by live cells. F: Retinal endothelial cell apoptosis was evaluated by caspase-3/7 activation. As a positive
control of apoptosis induction, cells were treated with 100 nmol/l staurosporine (STP) for 6 h. The results represent the mean  SEM of at least
four independent experiments and are expressed relative to control (Ctrl). **P < 0.01, signiﬁcantly different from control as determined by
ANOVA followed by Dunnett post hoc test.
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reactivity appeared as a near continuous staining at the
cell border (Fig. 2G and supplementary Fig. 1, available
in an online appendix). Upon TNF- treatment, a loss of
both ZO-1 and claudin-5 immunostaining was observed,
leading to a fragmented border staining, although the
effect on ZO-1 was more pronounced. Also, a diffuse
cytoplasmic distribution of claudin-5 and occludin was
observed in TNF-–treated cells. After TNF- treatment,
occludin staining increased, and it was irregularly dis-
tributed at the cell border (Fig. 2G and supplementary
Fig. 1).
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FIG. 2. TNF- alters tight junction proteins content
and cell localization. BRECs were treated with 5
ng/ml TNF- for 0.5 and 6 h. Whole-cell extracts
were assayed for ZO-1 (A), claudin-5 (B), and occlu-
din (C) immunoreactivity by Western blotting. Rep-
resentative Western blots for each tight junction
protein and -actin (loading control) are presented
above each respective graph. The results are nor-
malized to -actin and represent the mean SEM of
at least ﬁve independent experiments and are ex-
pressed as the relative amount compared with con-
trol (Ctrl). *P < 0.05, **P < 0.01, signiﬁcantly
different from control as determined by ANOVA
followed by Dunnett post hoc test. Total RNA was
isolated after6ho fTNF- treatment, and the
transcript levels of ZO-1 (D), claudin-5 (E), and
occludin (F) were analyzed by qPCR. Glyceralde-
hyde-3-phosphate dehydrogenase was used as an
endogenous control. Results represent the mean 
SEM of eight independent experiments and are
expressed as the relative amount compared with
control conditions. *P < 0.05, ***P < 0.001, signiﬁ-
cantly different from control as determined by Student t test. G: Cells were immunolabeled for ZO-1, claudin-5, and occludin 6 h after TNF- treatment,
and 10 confocal Z-stacks were taken through 2.56 m and projected into one image. Arrows indicate continuous staining at cell borders. These results
are representative of four independent experiments. Scale bar, 25 m.
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meability. The effect of the glucocorticoid dexametha-
sone on TNF-–induced endothelial permeability was
determined. BRECs were treated with 50 ng/ml dexameth-
asone 18 h before TNF- treatment. The increase in cell
permeability induced by TNF- was completely prevented
by dexamethasone (Fig. 3A). To investigate if the effect of
dexamethasone was dependent on transcriptional activa-
tion by the glucocorticoid receptor, BRECs were pre-
treated with 5 mol/l RU486, a glucocorticoid receptor
antagonist that inhibits the transactivation function of this
receptor (35). A 1-h pretreatment of RU486 before the
addition of dexamethasone signiﬁcantly reduced the pro-
tective effect of dexamethasone on TNF-–induced cell
permeability (Fig. 3B). RU486 alone had no effect on
permeability and did not alter the TNF- response but did
prevent the dexamethasone reduction in permeabilitiy as
previously reported (36). These data show that dexa-
methasone’s protective effect is partially due to glu-
cocorticoid receptor transactivation but also suggest
that transrepression of TNF-–responsive transcription
factors also contributes to the inhibition of TNF-–in-
duced cell permeability.
Dexamethasone prevents TNF-–induced alterations
in tight junction proteins. The effect of dexamethasone
on TNF-–induced changes in tight junction protein con-
tent and cellular localization was also evaluated. Dexa-
methasone alone signiﬁcantly increased ZO-1, claudin-5,
and occludin protein content (Fig. 4). TNF- decreased
ZO-1 and claudin-5 protein content and these effects were
prevented by dexamethasone pretreatment (Fig. 4A and
B), whereas dexamethasone and TNF- treatment yielded
an additive threefold increase in occludin protein content
(Fig. 4C). Dexamethasone increased ZO-1, claudin-5, and
occludin staining at the cell border and prevented the
TNF-–induced fragmentation of these tight junction pro-
teins (Fig. 4D and supplementary Fig. 1).
NF-B inhibition reduces TNF-–induced cell perme-
ability. The involvement of NF-B activation in TNF-–
induced endothelial permeability was investigated. BRECs
were exposed to 1 mol/l 

 VII, an IB kinase complex
inhibitor, 30 min before TNF- addition. As a control for
inhibitor I

 VII effectiveness, TNF--induced IB phos-
phorylation by I

 was evaluated. Figure 5A shows that
IB phosphorylation was blocked by I

 VII. The TNF-
–induced increase in permeability (275.0 
 46.7% of
control) was signiﬁcantly reduced by I

 VII (160.5 

21.7% of control; Fig. 5B). The effect of adenovirus-
mediated overexpression of IB on cell permeability was
also evaluated. Western blotting was used to conﬁrm the
adenovirus-mediated expression of GFP and IB 30 h
after adenoviral infection. GFP expression was similar in
both AdEmpty- and AdIB-transduced cells, while IB
was heavily expressed in AdIB-transduced cells com-
pared with AdEmpty-transduced cells (Fig. 5C). The ability
of IB overexpression to inhibit NF-B activation was
evaluated by examining the TNF-–induced expression of
IL-8 mRNA, a transcriptional target of NF-B. In both
nontransduced and AdEmpty-transduced cells, IL-8 mRNA
levels were signiﬁcantly increased (by 18- and 16-fold,
respectively) after2ho fTNF- stimulation (Fig. 5D). This
increase in IL-8 expression was signiﬁcantly reduced (by
41%) in AdIB-transduced cells, demonstrating that ade-
novirus-mediated overexpression of IB effectively
blocked NF-B activation after TNF- treatment. Subse-
quently, the effect of IB overexpression on TNF-–
induced cell permeability was determined. In AdEmpty-
transduced cells, TNF- induced a signiﬁcant increase in
cell permeability (273.6 
 71.0% of control; Fig. 5E),
similar to nontransduced cells (Fig. 5E). IB overexpres-
sion reduced TNF-–induced permeability to 157.5 
 5.7%
of control. These data suggest that NF-B activation is
necessary for a substantial part of the TNF-–induced
changes in BREC permeability.
PKCI-1 inhibits NF-B activation induced by TNF-.
PKC has a critical role in the activation of the NF-B
pathway (37). To determine whether PKC modulates
NF-B activation in retinal endothelial cells induced by
TNF-, the effect of PKCI-1, a novel PKC inhibitor with
little or no inhibitory activity on PKC or PKC (manu-
script in preparation), on TNF-–induced IL-8 mRNA
expression, was evaluated. BRECs were treated with 10
mol/l PKCI-1 30 min before treatment of cells with
TNF- for 2 h. TNF- induced a signiﬁcant 14-fold increase
in IL-8 transcripts, which was signiﬁcantly reduced to
6-fold by PKCI-1 (Fig. 6A). The effect of PKCI-1 on
TNF-–induced NF-B reporter activity was investigated
in a 293/NF-B/luc stable reporter cell line. Cells were
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(Ctrl). *P < 0.05, ***P < 0.001, signiﬁcantly different as determined by ANOVA followed by Bonferroni post hoc test.
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addition of TNF- for 6 h, and luciferase activity was
determined in whole-cell lysates. The results show that
PKCI-1 signiﬁcantly decreased TNF-–induced NF-B-
responsive luciferase expression in these cells (Fig. 6B).
These observations suggest that pharmacological inhibi-
tion of PKC reduces NF-B activation in response to
TNF-.
TNF-–induced cell permeability requires PKC.
PKC activation can occur downstream of the PI3K path-
way (38), which has been shown to be activated by TNF-
in vascular endothelial cells (39). Therefore, the effect of
PI3K/PKC pathway inhibition on retinal endothelial cell
permeability was investigated. BRECs were treated with 2
mol/l LY294002, a PI3K inhibitor, 30 min before the
treatment with TNF- for 6 h. The increase in cell perme-
ability induced by TNF- was signiﬁcantly inhibited by 56%
in the presence of LY294002 (Fig. 7A). Next, BRECs were
exposed to 10 mol/l PKCI-1 or the myristoylated
pseudosubstrate inhibitor of PKC (PKCp; 250 nmol/l) 30
min prior to TNF- addition. Both PKCI-1 and PKCp
completely suppressed the increase in cell permeability
induced by TNF- (Fig. 7B and C). Because conventional
PKC isoforms contribute to the VEGF-induced perme-
ability in retinal endothelial cells (23), the contributions
of conventional and novel PKC isoforms for TNF-–
induced cell permeability were also evaluated. BRECs
were treated with 5 mol/l BIM I (inhibitor of conven-
tional and novel PKC isoforms) or with 30 nmol/l PKC
inhibitor 30 min before TNF- treatment. These inhibi-
tors had no effect on TNF-–induced cell permeability
(supplementary Fig. 2A and B, available in an online
appendix). These results suggest that PKC, but not
conventional and novel PKC isoforms, mediate TNF-–
induced retinal endothelial cell permeability. The effect
of PKC inhibition on tight junction protein content in
TNF-–treated BRECs was also evaluated. The protein
content of ZO-1, claudin-5, and occludin was not af-
fected by treatment with PKCI-1. However, the de-
crease in ZO-1 and claudin-5 protein levels induced by
TNF- was effectively prevented by PKCI-1 (Fig. 7E
and F). Surprisingly, in the presence of PKCI-1, TNF-
still caused an increase in occludin protein content,
which actually was greater than the effect of TNF-
alone (Fig. 7G).
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FIG. 4. Dexamethasone prevents TNF-–induced alter-
ations in the tight junction complex. Conﬂuent BRECs
were treated with 50 ng/ml Dex 18 h before TNF- treat-
ment (5 ng/ml, 6 h). Whole-cell extracts were assayed for
(A) ZO-1, (B) claudin-5, and (C) occludin immunoreactiv-
ity by Western blotting as described in RESEARCH DESIGN AND
METHODS. Representative Western blots for each tight junc-
tion protein and -actin (loading control) are presented
above each respective graph. The results are normalized to
-actin and represent the mean  SEM of at least ﬁve
independent experiments and are expressed as the rela-
tive amount compared with control. *P < 0.05, **P < 0.01,
***P < 0.001, signiﬁcantly different from control; #P <
0.05, ##P < 0.01, ###P < 0.001, signiﬁcantly different from
TNF-, as determined by ANOVA followed by Bonferroni
post hoc test. D: Cells were immunolabeled for ZO-1,
claudin-5, and occludin and 10 confocal Z-stacks were
taken through 2.56 m and projected into one image.
These results are representative of four independent ex-
periments. Scale bar, 25 m.
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in vivo. The effect of PKCI-1 on TNF-–induced BRB
permeability was evaluated in vivo by the Evans blue
assay. The injection of TNF- in the vitreous induced the
accumulation of Evans blue (20.30 
 2.46 l plasma/g/h)
as compared with PBS-injected animals (10.25 
 2.48 l
plasma/g/h; Fig. 8A). PKCI-1 alone had no effect on the
accumulation of Evans blue but completely prevented
TNF-–induced accumulation of the dye. To determine the
effect of TNF- injection and PKC inhibition on retinal
vascular tight junction organization, retina whole ﬂat
mounts were immunolabeled for ZO-1 and occludin pro-
teins after injection of the cytokine or cytokine with
PKCI-1. In PBS-injected rat eyes, ZO-1 and occludin
immunoreactivities were intense and localized at the junc-
tions of the cell membranes of endothelial cells in retinal
vessels. In TNF--injected eyes, changes in ZO-1 immuno-
staining were particularly evident, which became mark-
edly reduced and intermittently absent from the cell
borders. These alterations were prevented by cotreatment
with PKCI-1 (Fig. 8B). Consistent with the results ob-
tained with BRECs in culture, the occludin content was
not reduced with TNF- but displayed regions with disor-
ganized cell-border labeling that were reversed by PKCI-1
treatment.
DISCUSSION
Elevated levels of proinﬂammatory cytokines IL-1 and
TNF- have been detected in the vitreous of diabetic
patients with retinopathy (10,11) and in diabetic rat retinas
correlated with increased vascular permeability (12,40).
However, the mechanisms underlying the effects of IL-1
and TNF- on retinal microvascular barrier have not been
addressed. The results presented herein demonstrate that
IL-1 and TNF- increase retinal endothelial cell perme-
ability and that TNF- acts through PKC/NF-B to reduce
the expression and alter the distribution of the tight
+
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monolayer permeability to 70 kDa dextran was measured as
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ticoid treatment completely prevented the TNF-–induced
increase in retinal endothelial cell permeability through
both transactivation of the glucocorticoid receptor and
transrepression of the NF-B signaling pathway. Pharma-
cological inhibition of PKC reduced NF-B activation and
prevented TNF-–induced retinal endothelial cell perme-
ability both in vitro and in vivo.
The increase in retinal vascular permeability is associ-
ated with changes in the expression or distribution of the
tight junction proteins. The content of occludin and ZO-1
decreases in the retinas of diabetic animals (18,33,41). In
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sion and decreased the junctional localization of both
proteins, which was associated with an increase in cell
permeability. These studies are consistent with previous
publications demonstrating reduced claudin-5 gene ex-
pression after TNF- treatment in brain capillary endothe-
lial cells (42,43). However, in these same studies, a
decrease in occludin was observed after TNF- treatment,
which contrast the increase in occludin observed in the
present study. Further, TNF- reduced occludin promoter
activity in a human intestinal cell line (44). The cause for
this difference is unclear but may relate to the use of cell
lines versus primary culture or differences in epithelial and
endothelial cell types. Regardless, TNF- consistently re-
duces both claudin-5 and ZO-1 expression, two tight
junction proteins essential for barrier properties.
The effect of TNF- and VEGF on retinal endothelial
permeability is distinct. Occludin becomes phosphory-
lated on multiple sites after VEGF treatment in a conven-
tional PKC-dependent manner (23) and Ser490 has
recently been identiﬁed as a phosphorylation site neces-
sary for VEGF-induced permeability (24,45). TNF- did not
lead to an increase in occludin phosphorylation on Ser490
(data not shown) but rather led to an increase in occludin
expression. Further, inhibition of conventional or novel
PKC isoforms did not prevent TNF-–induced permeabil-
ity. These data demonstrate that VEGF and TNF- alter
retinal endothelial barrier properties by distinct molecular
mechanisms.
The data presented here suggest that glucocorticoid
receptor activation inhibits TNF-–induced cell permeabil-
ity through both transactivation and transrepression
mechanisms. Inhibition of IKK and adenovirus-mediated
overexpression of IB blocked the increase in BREC
permeability induced by TNF- treatment. Together, these
data demonstrate that TNF-–induced retinal endothelial
cell permeability is mediated, at least in part, by NF-B.
The mechanisms by which NF-B may regulate cell per-
meability and the tight junction complex are largely un-
known. NF-B putative binding sites and several E-box
sequences were identiﬁed within the claudin-5 promoter
sequence (43). Recent studies demonstrated that NF-B
induces the expression of Snail and Slug transcription
factors (46,47), which repress E-cadherin, occludin, and
claudin family members gene expression by binding to
speciﬁc E-box sequences during epithelial-mesenchymal
transition (48–50) These reports suggest the possibility
that a similar regulation by transcriptional repressors
might also play a role in claudin-5 and ZO-1 expression in
retinal endothelial cells.
PKC has been shown to contribute a critical and
selective role in the regulation of NF-B. In PKC-deﬁcient
mice, NF-B transcriptional activity as well as the phos-
phorylation of p65 in response to TNF- is severely
impaired (37). In endothelial cells, the transcriptional
activity of NF-B is dependent on the phosphorylation of
the p65 subunit by PKC (51). The observations that
TNF-–induced increase in IL-8 expression and NF-B-
dependent luciferase reporter expression are inhibited by
PKCI-1 further support the hypothesis that PKC is im-
portant for NF-B transcriptional activity.
In endothelial cells, PKC has been shown to be acti-
vated by TNF- (51–53). The mechanism of activation of
PKC remains to be fully clariﬁed, but it has been shown to
be an important downstream target of PI3K (38). TNF-
stimulates PI3K in endothelial cells through endothelial/
epithelial tyrosine kinase induced activation of VEGFR2
(39). Interestingly, this is only a partial activation of
VEGFR2 that fails to activate the classical PKC isoforms
necessary for VEGF-stimulated permeability (23,54). PI3K
inhibition and inhibition of its downstream target PKC
(38) blocked TNF-–induced cell permeability, whereas
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FIG. 8. PKCI-1 prevents TNF-–induced retinal vascular permeability
in vivo. Animals’ eyes were injected with PBS with 0.1% BSA, TNF-
(10 ng); PKCI-1 (280 ng); or with both PKCI-1 and TNF-. A: Evans
blue leakage was evaluated 24 h after intravitreous injections. The
results represent the mean  SEM (n  7–8 animals per group) and are
expressed relative to control (Ctrl; PBS-injected eyes). **P < 0.01,
signiﬁcantly different from control; ##P < 0.01, signiﬁcantly different
from TNF-, as determined by ANOVA followed by Bonferroni post hoc
test. B: PKCI-1 prevents the alterations in tight junction proteins
induced by TNF- in vivo. Whole retinas were immunolabeled for ZO-1
and occludin 4 h after injection. Images were obtained on a Leica TCS
SP2 AOBS confocal microscope and are presented as a maximum
projection. Arrows indicate loss and/or discontinuous cell border
staining. Scale bar, 25 m. (A high-quality digital representation of
this ﬁgure is available in the online issue.)
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NF-B activation and most likely inhibited additional
signaling pathways that contribute to the regulation of the
tight junction complex and endothelial permeability in-
duced by TNF-. PKCI-1 is also effective at blocking
VEGF-induced permeability (manuscript in preparation).
Then, although VEGF and TNF- alter the tight junction
complex by distinct mechanisms, inhibition of PKC is a
common target for blocking both VEGF- and TNF-–
induced cell permeability. Therefore, targeting PKC may
provide a speciﬁc therapeutic option for the prevention of
vascular permeability in retinal diseases with elevated
TNF- and VEGF, such as diabetic retinopathy.
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